Testing a Multilevel, Culturally Appropriate Lifestyle Intervention For Hispanic Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
NCT07199491 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64
Last updated 2026-03-03
Summary
The purpose of this study is to understand if a behavioral lifestyle intervention called the Healthy Liver/Hígado Sano program can help Hispanic/Latino patients with metabolic dysfunction associated steatotic liver disease (MASLD), also known as non-alcoholic fatty liver disease (NAFLD), lose weight and improve their liver health
Conditions
- Metabolic-dysfunction Associated Liver Disease (MASLD)
Interventions
- BEHAVIORAL
-
Healthy Liver/Hígado Sano program
Participants will attend 16 educational classes over a 6-month period. These sessions are facilitated by a lifestyle coach in a group setting and last about an hour. Family members attend the sessions with the participant. Additionally, providers and staff at the clinic receive training on MASLD background information, including MASLD management, and motivational interviewing. Clinic community health workers and/or social workers assess participants for unmet social needs and refer as appropriate to social services.
- BEHAVIORAL
-
Usual Care
Observational clinic participants receive usual care, which can include referrals to dieticians and/or specialists.
Sponsors & Collaborators
-
National Institute on Minority Health and Health Disparities (NIMHD)
collaborator NIH -
The University of Texas Health Science Center, Houston
lead OTHER
Principal Investigators
-
Natalia Heredia · The University of Texas Health Science Center, Houston
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-01-29
- Primary Completion
- 2027-10-31
- Completion
- 2027-10-31
Countries
- United States
Study Locations
More Related Trials
-
Acceptability and Feasibility of a New Approach to Engage Patients With Steatotic Liver Disease in Physical Activity
NCT06446908 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study
NCT07188220 ·Status: RECRUITING
-
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
NCT03587831 ·Status: RECRUITING ·Phase: NA
-
Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis
NCT01950884 ·Status: UNKNOWN ·Phase: PHASE4
-
Ambulatory Liver Fat Monitoring in Patients With Non-alcoholic Fatty Liver Disease
NCT05754385 ·Status: COMPLETED ·Phase: NA
-
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
NCT05292911 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis
NCT05065593 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
NCT05357352 ·Status: COMPLETED
-
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
NCT05560607 ·Status: COMPLETED ·Phase: PHASE1
-
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
NCT05006885 ·Status: COMPLETED ·Phase: PHASE1
-
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
NCT01002547 ·Status: COMPLETED ·Phase: PHASE4
-
Influence of Diabetic Control on the Degree of Liver Fibrosis Assessed by Non-invasive Scores in Patients Followed in Diabetology
NCT05605821 ·Status: NOT_YET_RECRUITING
-
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT05395481 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Manual Therapy in Metabolic Liver Disease
NCT06338618 ·Status: COMPLETED ·Phase: NA
-
Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes
NCT07270822 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease
NCT04988204 ·Status: COMPLETED ·Phase: NA
-
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
NCT06764056 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of Metabolic Dysfunction-Associated Steatotic Liver Disease Among Sohag University Employees
NCT06536933 ·Status: NOT_YET_RECRUITING
-
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
NCT06195943 ·Status: COMPLETED ·Phase: NA
-
Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.
NCT04579874 ·Status: COMPLETED ·Phase: NA
-
Assessment of Non-Invasive Testing in Major Liver-Related Outcomes
NCT06986447 ·Status: ENROLLING_BY_INVITATION
-
NASH Patient's Itinerary: Comparison of Strategies for Screening, Referring and Management of Diabetic Patients
NCT06688149 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
NCT06836609 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Quantifying Hepatic Mitochondrial Fluxes in Humans
NCT05305287 ·Status: RECRUITING ·Phase: PHASE4